Abstract
Background Genomic alterations in BRCA1/2 and genomic scar signatures are associated with homologous recombination DNA repair deficiency (HRD) and serve as therapeutic biomarkers for platinum and PARP inhibitors in breast and ovarian cancers. However, the clinical significance of these biomarkers in other homologous recombination repair-related genes or other cancer types is not fully understood.
Results We analyzed the datasets of all solid cancers from The Cancer Genome Atlas and Cancer Cell Line Encyclopedia, and found that the association between biallelic alterations in the homologous recombination pathway genes and genomic scar signatures differed greatly depending on gender and the presence of somatic TP53 mutation. Additionally, HRD cases identified by a combination of these indicators showed higher sensitivity to DNA-damaging drugs than non-HRD cases both in clinical samples and cell lines.
Conclusion Our work provides novel proof of the utility of HRD analysis for all cancer types and will improve the precision and efficacy of chemotherapy selection in clinical oncology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is currently no funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Open access data and processed data for TCGA samples are available from the cBioPortal (https://www.cbioportal.org/), the Broad GDAC (https://gdac.broadinstitute.org/), and the GDC Pan-Cancer Atlas studies (https://gdc.cancer.gov/about-data/publications/pancanatlas). Controlled access data including germline variant annotations, raw sequence data, and raw SNP array data are available through the dbGaP-authorized access system (study accession phs000178). CCLE cell line datasets and their drug sensitivity data are available in the DepMap portal (https://depmap.org/portal/), the COSMIC cell line project (https://cancer.sanger.ac.uk/cell_lines), and Genomics of Drug Sensitivity in Cancer (https://www.cancerrxgene.org/) . The processed data and codes to reproduce the main results of this work are available on the GitHub page (https://github.com/shirotak/pancancer_hrd_analysis). Other codes for preprocessing public or restricted-access data are available from the corresponding author upon reasonable request.
